A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Trial ID or NCT#

NCT00724334

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Official Title

An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Completion of MF-TG101348-001 study - Diagnosis of myelofibrosis - At least 18 years of age
Exclusion Criteria:
  1. - Any acute or chronic medical abnormality that may increase the risk associated with study participation
View All Criteria
Show Less

Investigator(s)

Jason Gotlib
Hematologist-Oncologist
Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov